A Phase II Clinical Study of mFOLFOX6 /XELOX as Adjuvant Chemotherapy after Curative Resection of Stage III Colon Cancer: The FACOS Study

This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are bein...

Full description

Saved in:
Bibliographic Details
Published inAnnals of Cancer Research and Therapy Vol. 24; no. 1; pp. 17 - 22
Main Authors Ishibashi, Keiichiro, Kumamoto, Kensuke, Koda, Keiji, Kato, Hiroyuki, Nishimura, Genichi, Yoshimatsu, Kazuhiko, Yokomizo, Hajime, Ooki, Shinji, Tanaka, Soichi, Asano, Michio, Yokoyama, Masaru, Kawada, Tomoyuki, Ishida, Hideyuki
Format Journal Article
LanguageEnglish
Published The Japanese Society of Strategies for Cancer Research and Therapy 2016
Subjects
adjuvant chemotherapy
colon cancer
oxaliplatin
Online AccessGet full text

Cover

More Information
Summary:This clinical study is being conducted to verify the efficacy and safety of oxaliplatin combined with a fluoropyrimidine derivative as adjuvant chemotherapy for patients with stage III colon cancer, since few clinical data are available for Japanese patients. The mFOLFOX6 and XELOX regimens are being investigated. The primary endpoint is 3-year disease-free survival, while the secondary endpoints are safety, the completion rate of study therapy, 2-year disease-free survival, and overall survival. It is planned to enroll 130 patients.
ISSN:1344-6835
1880-5469
DOI:10.4993/acrt.24.17